Amit Bahl
Overview
Explore the profile of Amit Bahl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
224
Citations
2848
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aprikian A, Bahl A, Omlin A, Baciarello G, Chakravarty A, Kondaparthi P, et al.
Front Oncol
. 2025 Feb;
15:1491314.
PMID: 39995831
Introduction: Androgen-receptor pathway inhibitors such as abiraterone and enzalutamide have demonstrated clinical benefit in patients with metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to conduct a...
2.
Bahl A, Johnson S, Mielke N, Blaivas M, Blaivas L
J Vasc Access
. 2025 Jan;
11297298241307055.
PMID: 39831402
Objective: Peripheral intravenous catheter (PIVC) failure occurs in approximately 50% of insertions. Unexpected PIVC failure leads to treatment delays, longer hospitalizations, and increased risk of patient harm. In current practice...
3.
Glen H, Bahl A, Fleure L, Clarke N, Jain S, Kalsi T, et al.
BMJ Open
. 2024 Nov;
14(11):e090013.
PMID: 39609017
Objectives: This study aimed to determine the clinical utility of the androgen deprivation therapy (ADT)+docetaxel (DOCE)+androgen receptor-targeted agent (ARTA) triplet therapy in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in...
4.
Bahl A, Sodatonou H, Snjider R, Chilelli A, Pranzo A, Martins K, et al.
World J Urol
. 2024 Oct;
42(1):584.
PMID: 39422767
Purpose: To determine new-onset or worsening T2DM risk in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone acetate (AA) vs. enzalutamide (ENZA) in England. Methods: Records of patients on...
5.
Bahl A, Xing Y, Gibson S, DiLoreto E
PLoS One
. 2024 Oct;
19(10):e0310676.
PMID: 39352905
Objective: Education and training in vascular access is a critical component to delivering quality vascular access care. Given that organizations must invest resources to implement and sustain high-quality vascular access...
6.
Bahl A, Gibson S, Walton A
Ther Clin Risk Manag
. 2024 Sep;
20:559-566.
PMID: 39247171
Objective: Modifying the PIVC tip to direct infusates toward areas of highest hemodilution may reduce vein wall damage. This study compared flow patterns between a traditional PIVC with a central...
7.
Gibson S, Sarlabous J, Adair L, Bahl A
J Nurs Care Qual
. 2024 Aug;
40(1):56-61.
PMID: 39151043
Background: Education and training may improve outcomes within an experienced vascular access team. Purpose: The purpose of this study was to measure the impact of a standardized peripheral intravenous catheter...
8.
Mielke N, OSullivan C, Xing Y, Bahl A
Int J Equity Health
. 2024 Aug;
23(1):158.
PMID: 39134999
Background: Placement of peripheral intravenous catheters (PIVC) is a routine procedure in hospital settings. The primary objective is to explore the relationship between healthcare inequities and PIVC outcomes. Methods: This...
9.
Sharma A, Bahl A, Frazer R, Godhania E, Halfpenny N, Hartl K, et al.
Cancers (Basel)
. 2024 Aug;
16(15).
PMID: 39123435
Background: We conducted a systematic literature review (SLR) to identify clinical evidence on treatments in advanced renal cell carcinoma (aRCC) after the failure of prior therapy with cytokines, tyrosine kinase...
10.
Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, et al.
Urol Oncol
. 2024 Jul;
42(11):372.e1-372.e10.
PMID: 39025719
Background: Taxane- based chemotherapy is widely used in patients with platinum- and immunotherapy refractory, metastatic urothelial carcinoma (mUC). Outcomes are poor and biomarkers associated with outcome are lacking. We aim...